[Pilot study of the action of Doqualast on dietary hyperuricemia in volunteers].

Abstract

For eight days 8 healthy volunteers were treated with a formula diet and additional 1680 purine base per day. Beginning with day 5, doqualast was administered orally in a dosage of 200 mg t.i.d. Serum uric acid level was lowered by doqualast from 7.84 +/- 0.9 mg/dl to 5.09 +/- 0.8 mg/dl (p less than 0.01). Uric acid clearance increased from 7.6 +/- 2.5 ml/min to 11.5 +/- 2.4 ml/min (p less than 0.05). Excretion of uric acid in urine increased from 622 +/- 231 mg/d to 890 +/- 233 mg/d at the end of therapy. Total cholesterol in serum was lowered from 222 +/- 70 mg/dl to 159 +/- 48 mg/dl (p less than 0.05). The new uric acid lowering drug doqualast was well tolerated clinically. No adverse effects on biochemistry parameters were observed.

• Authors: F Matzkies, R Stechert, G Rauber, F Matzkies Jr, U Drescher
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 39 Issue 9 Pg. 1171-2 (Sep 1989) ISSN: 0004-4172 [Print] Germany
• Vernacular Title: Pilotstudie zur Wirkung von Doqualast bei diätetisch erzeugter Hyperurikämie an Probanden.
• PMID: 2574040 (Publication Type: English Abstract, Journal Article)

Chemical References

• Histamine H1 Antagonists
• Quinazolines
• Uric Acid
• Cholesterol
• doqualast

Topics

• Adult
• Cholesterol (blood)
• Diet
• Food, Formulated
• Histamine H1 Antagonists (adverse effects, pharmacology)
• Humans
• Male
• Pilot Projects
• Quinazolines (adverse effects, pharmacology)
• Uric Acid (blood)